Heterocyclic fused gamma-carboline compound, pharmaceutical composition, preparation method and application thereof
By developing new 5-HT receptor agonists, the problems of slow onset of existing antidepressants and insufficient response in patients have been solved, and selective arousal of 5-HT receptors have been achieved, providing faster and safer antidepressant treatment effects.
CN119707971APending Publication Date: 2025-03-28SHANDONG LUYE PHARMACEUTICAL CO LTD
0 Cites 1 Cited by
Patent Information
- Application Number
- CN202411360706.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2024-02-06
- Filing Date
- 2024-09-27
- Publication Date
- 2025-03-28
AI Technical Summary
Technical Problem
The onset of existing antidepressants is slow, with about 30-60% of patients not responding sufficiently to the initial treatment drugs. Although new drugs such as esketamine take effect quickly, they have a risk of sedation, cognitive impairment and abuse, which limits their clinical application.
Method used
A novel structure of 5-HT receptor agonist was developed to achieve selective agonism of 5-HT receptors by synthesizing heterocyclic fused gamma-carboline compounds of specific structures.
Benefits of technology
This compound shows good 5-HT receptor agonism activity, potentially used to treat and prevent various CNS diseases, providing faster and safer antidepressant effects.
✦ Generated by Eureka AI based on patent content.
Abstract
The invention relates to a heterocyclic fused gamma-carboline compound, or a pharmaceutically acceptable salt thereof, or a stereoisomer thereof, and a pharmaceutical composition containing the heterocyclic fused gamma-carboline compound. The compounds, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, and pharmaceutical compositions have agonistic activity against 5-HT receptors, and can be used as 5-HT receptor agonists for the prevention or treatment of diseases or various CNS diseases or conditions related to the activity or expression level of 5-HT receptors. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art